Benzinga | Nov 5, 2020 08:13AM EST

Outlook Therapeutics Secures $10M In Additional Working Capital Through Issuance Of Promissory Note To Accredited Investor

MONMOUTH JUNCTION, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), alate clinical-stagebiopharmaceutical companyworking to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikgfor use in retinalindications, today announced the issuance of a $10.2 million unsecured promissory note (the "Note") to an accredited investor for $10.0 million cash proceeds, which will be used to pay off existing demand notes and to provide additional working capital.